Most Popular
-
1
Now is no time to add pressure on businesses: top executives
-
2
CJ CheilJedang to spur overseas growth with new Hungary, US plants
-
3
Blackpink's solo journeys: Complementary paths, not competition
-
4
Nationwide rail disruptions feared as union plans strike from Dec. 5
-
5
Seoul to host winter festival from Dec. 13
-
6
N. Korea, Russia court softer image: From animal diplomacy to tourism
-
7
Smugglers caught disguising 230 tons of Chinese black beans as diesel exhaust fluid
-
8
[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts
![[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/21/20241121050099_0.jpg&u=20241121172748)
-
9
Main opposition pushes to ease, not postpone, tax on crypto gains
-
10
Actor Song Joong-ki welcomes second child in Rome
![[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/21/20241121050099_0.jpg&u=20241121172748)
[DISCLOSURE] Boryung Pharmaceutical (003850) reported on Oct. 4 that it has signed a technology introduction contract with PharmaMar of Spain for rights to launch and commercialize Aplidin, a treatment option for multiple myeloma, in Korea.
By Yun Jeong-hyeon (clareyun@heraldcorp.com)
By Yun Jeong-hyeon (clareyun@heraldcorp.com)
![[Today’s K-pop] Babymonster logs 100m views with ‘Drip’ music video](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=642&simg=/content/image/2024/11/22/20241122050051_0.jpg&u=20241122172213)